BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”),

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy a

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raise

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares

Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead

https://www.sec.gov/ix?doc=/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”),

In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. K

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targetin

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting r

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transc

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or

RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consens

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the ana

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year f

Ocular Therapeutix (NASDAQ: OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the c

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successf

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal dis

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise

Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raise

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February

Needham analyst Serge Belanger maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and lowers t

Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite mee

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h

MDT: -5% | Medtronic Q3 Adj. EPS $1.36 Beats $1.33 Estimate, Sales $9.017B Beat $8.905B Estimate  

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.29) per share which beat the analy